JUNIO 2008
{phocadownload view=file|id=38|target=_blank|text=Nuevos farmacos hipotensores 2007}
• Ritz E and Wanner C.Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol (Jun) 19:1065-1071, 2008
• Parienti JJ, Thirion M, Megarbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. J Am Med Assoc (May) 299:2413-2422, 2008
• Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol (May) 19:999-1007, 2008
• Mathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol (Jun) 19:1092-1105, 2008
• Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study . Kidney Int (Jun) 73:1303-1309, 2008
• Weiner DE, Tighiouart H, Elsayed EF, et al. Uric acid and incident kidney disease in the community . J Am Soc Nephrol (Jun) 19:1204-1211, 2008
• Fogazzi GB, Verdesca S, Garigali G. Urinalysis: core curriculum 2008.
Am J Kidney Dis (Jun) 51:1052-1067, 2008
• Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med (Jun) 358:2433-2446, 2008
